Study Reviews Evidence Supporting Use of Cannabinoids to Treat ALS

March 1, 2017 - als

The journal Neural Regeneration Research has published a examination detailing a latest commentary in a use of cannabis-derived compounds to provide amyotrophic parallel sclerosis (ALS).

The review, “Can cannabinoids be a intensity healing apparatus in amyotrophic parallel sclerosis?,” records that to date, a usually accessible therapy for ALS patients is riluzole, that controls neuronal signaling. However, this drug has singular healing value and usually tolerably increases presence — definition novel and some-more effective therapeutic options for ALS patients are still needed.

Cannabinoids, a bioactive compounds of Cannabis sativa, strive their activity by contracting to a CB1 and CB2 receptors.

The cannabinoid complement seems to be concerned in a pathology of ALS. Indeed, a spinal cord of ALS patients has been shown to benefaction engine neuron repairs triggered by defence system’s cells (microglia and macrophages) that demonstrate increasing levels of a CB2 cannabinoid receptor.

“So all these information uncover how modifying CB2-mediated processes could change ALS course and how many a endocannabinoid complement is potentially concerned in shortening neuroinflammation, excitotoxicity and oxidative dungeon damage,” researchers wrote.

Previous studies have shown that cannabinoids have antioxidant, anti-inflammatory and neuroprotective actions in animal models of ALS. Indeed, cannabinoids can delay illness course and lengthen presence in these animals. However, usually a few studies have investigated a outcome of cannabinoids in tellurian patients, that creates it formidable to interpret a results.

“According to a singular observational investigate of patients with ALS, usually a 10 percent who certified immoderate cannabis revealed assuage service of several symptoms, including ardour loss, depression, pain and drooling,” researchers wrote. “In addition, spasticity is also a major problem for ALS patients, that reported that cannabis can subjectively urge spasticity.”

They added: “There is a current motive to introduce a use of cannabinoid compounds in a pharmacological government of ALS patients. Cannabinoids indeed are means to check ALS course and lengthen survival. However, many of a studies that investigated a neuroprotective intensity of these compounds in ALS were achieved in animal models, since a few clinical trials that investigated cannabinoids-based medicines were focused usually on a alleviation of ALS-related symptoms, not on a control of illness progression.”

The researchers pronounced they wish scientists will keep studying how cannabinoids might be of healing use for ALS patients.

Print FriendlyPrint This Page

source ⦿ https://alsnewstoday.com/2017/02/28/can-cannabinoids-be-a-potential-therapeutic-tool-in-amyotrophic-lateral-sclerosis/

More als ...

  • New ALS Molecule May Work to Delay Disease Progression, Says …New ALS Molecule May Work to Delay Disease Progression, Says … Researchers have developed a molecule called 123C4 that targets the EphA4 receptor, which is known to contribute to the development of amyotrophic lateral sclerosis (ALS), according to a […]
  • Researchers Develop New Molecule, 123C4, with Possibility to Treat ALSResearchers Develop New Molecule, 123C4, with Possibility to Treat ALS Researchers have developed a molecule called 123C4 that targets the EphA4 receptor, which is known to contribute to the development of amyotrophic lateral sclerosis (ALS), according to a […]
  • AT-1501AT-1501 AT-1501 (anti-CD40L) is an investigational drug being developed by Anelixis Therapeutics, a subsidiary of the ALS Therapy Development Institute (ALS TDI), to treat amyotrophic lateral […]

› tags: als /